Plasma total homocysteine levels in hyperthyroid and hypothyroid patients

Metabolism: Clinical and Experimental

Volumn 47, Issue 1, 1998, Pages 89-93

  Nedrebo B G ^b   Ericsson, U B ^b   Nygard O ^b   Refsum, H ^b   Ueland, P M ^b   Aakvaag, A ^b   Aanderud, S ^b   Lien, E A ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HOMOCYSTEINE;

ADULT; ARTICLE; ATHEROGENESIS; CARDIOVASCULAR DISEASE; FEMALE; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RISK FACTOR; THYROID DISEASE; THYROID FUNCTION;

EID: 0031934299     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(98)90198-6     Document Type: Article

References (29)

1. Steinberg AD: Myxedema and coronary artery disease - A comparative autopsy study. Ann Intern Med 68:338-344, 1968
2. Grytting G, Salvesen HA: Thyrotoxicosis and myocardial infarction. Acta Med Scand 57:169-171, 1957
3. Williams GH, Braunwald E: Endocrine and nutritional disorders and heart disease, in Braunwald E (ed): Heart Disease. Philadelphia, PA, Saunders, 1984, pp 1722-1747
4. Mason RL, Hunt HM, Hurxthal L: Blood cholesterol values in hyperthyroidism and hypothyroidism - Their significance. N Engl J Med 203:1273-1278, 1930
5. Gildea EF, Man EB, Peters IP: Serum lipids and proteins in hypothyroidism. J Clin Invest 18:739-755, 1939
6. Malmros H, Swahn B: Lipid metabolism in myxedema. Acta Med Scand 145:361-369, 1953
7. Becker C: Hypothyroidism and atherosclerotic heart disease: Pathogenesis, medical management, and the role of coronary bypass surgery. Endocr Rev 6:432-440, 1985
8. Masaki H, Nishikawa M, Urakami M, et al: 3,3′,5′-Triiodothyronine inhibits collagen-induced human platelet aggregation. J Clin Endocrinol Metab 75:721-725, 1992
9. Ishikawa T, Chijiwa T, Hagiwara M, et al: Thyroid hormones directly interact with vascular smooth muscle strips. Mol Pharmacol 35:760-765, 1989
10. Mamiya S, Hagiwara M, Inoue S, et al: Thyroid hormones inhibit platelet function and myosin light chain kinase. J Biol Chem 264:8575-8579, 1989
11. Boushey CJ, Beresford SAA, Omenn GS, et al: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: Probable benefits of increasing folic acid intakes. JAMA 274:1049-1057, 1995
12. Ueland PM, Refsum H: Plasma homocysteine, a risk factor for vascular disease: Plasma homocysteine in health, disease and drug therapy. J Lab Clin Med 114:473-501, 1989
13. Finkelstein JD: Methionine metabolism in mammals. J Nutr Biochem 1:228-237, 1990
14. Amesen E, Refsum H, Bønaa KH, et al: The Tromsø Study: Serum total homocysteine and coronary heart disease. Int J Epidemiol 24:704-709, 1995
15. Guttormsen AB, Ueland PM, Nesthus I, et al: Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (≥40 μmol/liter). The Hordaland Homocysteine Study. J Clin Invest 98:2147-2183, 1996
16. Fiskerstrand T, Refsum H, Kvalheim G, et al: Homocysteine and other thiols in plasma and urine: Automated determination and sample stability. Clin Chem 39:263-271, 1993
17. Dixon WJ: Book BMDP Statistical Software. Berkeley, CA, University of California Press, 1992
18. 12 levels in hyperthyroidism. Am J Haematol 31:233-236, 1992
19. 12 levels in hypothyroid and hyperthyroid patients. Arch Intern Med 135:701-704, 1975
20. 12) and folate deficiency. FASEB J 7:1344-1353, 1994
21. Nair CPP, Viswanathan G, Noronha J: Folate-mediated incorporation of ring-2-carbon of histidine into nucleic acids: Influence of thyroid hormone. Metabolism 43:1575-1578, 1994
22. Ingenbleek Y, Barclay D, Dirren H: Nutritional significance of alterations in serum amino acid patterns in goitrous patients. Am J Clin Nutr 43:310-319, 1986
23. Shirota T, Shinoda T, Yamada T, et al: Alteration of renal function in hyperthyroidism: Increased tubular secretion of creatinine and decreased tubule delivery of chloride. Metabolism 41:402-405, 1992
24. Discala VA, Kinney MJ: Effects of myxedema on the renal diluting and concentration mechanism. Am J Med 50:325-335, 1971
25. Dennis VW, Robinson K: Homocysteinemia and vascular disease in end-stage renal disease. Kidney Int 57:S11-S17, 1996 (suppl)
26. Mudd SH, Pool JR: Labile methyl balance for normal humans on various dietary regimens. Metabolism 24:721-733, 1975
27. Bostom AG, Shemin D, Lapane KL, et al: Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: A case-control study. Atherosclerosis 114:93-103, 1995
28. Guttormsen AB, Ueland PM, Svarstad E, et al: Kinetic basis of hyperhomocysteinemia in patients with chronic kidney failure. Kidney Int 52:495-502, 1997
29. Arnadottir M, Hultberg B, Nilsson-Ehle P, et al: The effect of reduced glomerular filtration rate on plasma total homocysteine concentration. Scand J Clin Lab Invest 56:41-46, 1996